This HTML5 document contains 32 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

PrefixNamespace IRI
dctermshttp://purl.org/dc/terms/
n26http://www.idref.fr/140218769/
marcrelhttp://id.loc.gov/vocabulary/relators/
n24http://www.idref.fr/075647834/
n20http://www.idref.fr/050177982/
n6http://www.idref.fr/145530892/
n15http://www.idref.fr/170111083/
n8http://www.idref.fr/130010855/
dchttp://purl.org/dc/elements/1.1/
n2https://hal.archives-ouvertes.fr/hal-03122586#
n5http://www.idref.fr/094593604/
n12http://www.idref.fr/097670987/
n13http://www.idref.fr/128768266/
n4http://www.idref.fr/075137119/
n25http://www.idref.fr/129296511/
bibohttp://purl.org/ontology/bibo/
n19http://www.idref.fr/067203779/
n21http://www.idref.fr/133049086/
n23http://www.idref.fr/260936324/
n7http://www.idref.fr/159782341/
n18http://www.idref.fr/183260945/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n27http://www.idref.fr/08363519X/
n17http://www.idref.fr/073740314/
xsdhhttp://www.w3.org/2001/XMLSchema#
n28http://www.idref.fr/082096112/
n9http://www.idref.fr/111746639/
n16http://www.idref.fr/067238351/
n14http://www.idref.fr/14439152X/
n10http://www.idref.fr/069553203/
Subject Item
n2:id
marcrel:aut
n4:id n5:id n6:id n7:id n8:id n9:id n10:id n12:id n13:id n14:id n15:id n16:id n17:id n18:id n19:id n20:id n21:id n23:id n24:id n25:id n26:id n27:id n28:id
dcterms:bibliographicCitation
Ghesquieres Hervé, Obéric Lucie, Morschhauser Franck, Tilly Herve, Ribrag Vincent, Lamy Thierry, Thieblemont Catherine, Maisonneuve Herve Gerard, Gressin Remy, Bouabdallah Krimo, Haioun Corinne, Damaj Gandhi, Fornecker Luc-Matthieu, Bouabdallah Reda, Feugier Pierre, Sibon David, Cartron Guillaume, Bonnet Christophe, André Marc, Chartier Loic, Ruminy Philippe, Kraeber-Bodere F, Bodet-Milin C, Berriolo-Riedinger Alina, Briere Josette, Jais Jean-Philippe, Molina Thierry, Itti Emmanuel, Casasnovas Olivier. Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA. Blood, 2021, 137 (17), pp.2307-2320. ⟨10.1182/blood.2020008750⟩ Ghesquieres Hervé, Obéric Lucie, Morschhauser Franck, Tilly Herve, Ribrag Vincent, Lamy Thierry, Thieblemont Catherine, Maisonneuve Herve Gerard, Gressin Remy, Bouabdallah Krimo, Haioun Corinne, Damaj Gandhi, Fornecker Luc-Matthieu, Bouabdallah Reda, Feugier Pierre, Sibon David, Cartron Guillaume, Bonnet Christophe, ANDRÉ Marc, Chartier Loic, Ruminy Philippe, Kraeber-Bodere F, Bodet-Milin C, Berriolo-Riedinger Alina, Briere Josette, Jais Jean-Philippe, Molina Thierry, Itti Emmanuel, Casasnovas Olivier. Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA. Blood, American Society of Hematology, 2021, 137 (17), pp.2307-2320. ⟨10.1182/blood.2020008750⟩ Ghesquieres Hervé, Obéric Lucie, Morschhauser Franck, Tilly Herve, Ribrag Vincent, Lamy Thierry, Thieblemont Catherine, Maisonneuve Herve Gerard, Gressin Remy, Bouabdallah Krimo, Haioun Corinne, Damaj Gandhi, Fornecker Luc-Matthieu, Bouabdallah Reda, Feugier Pierre, Sibon David, Cartron Guillaume, Bonnet Christophe, ANDRÉ Marc, Chartier Loic, Ruminy Philippe, Kraeber-Bodere F, Bodet-Milin C, Berriolo-Riedinger Alina, Briere Josette, Jais Jean-Philippe, Molina Thierry, Itti Emmanuel, Casasnovas Olivier. Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA. Blood, American Society of Hematology, 2020, 137 (17), pp.2307-2320. ⟨10.1182/blood.2020008750⟩ Ghesquieres Hervé, Obéric Lucie, Morschhauser Franck, Tilly Herve, Ribrag Vincent, Lamy Thierry, Thieblemont Catherine, Maisonneuve Herve Gerard, Gressin Remy, Bouabdallah Krimo, Haioun Corinne, Damaj Gandhi, Fornecker Luc-Matthieu, Bouabdallah Reda, Feugier Pierre, Sibon David, Cartron Guillaume, Bonnet Christophe, André Marc, Chartier Loic, Ruminy Philippe, Kraeber-Bodere F, Bodet-Milin C, Berriolo-Riedinger Alina, Briere Josette, Jais Jean-Philippe, Molina Thierry, Itti Emmanuel, Casasnovas Olivier . Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA . Blood, 2021, 137 (17), pp.2307-2320 . ⟨10.1182/blood.2020008750⟩ Ghesquieres Hervé, Obéric Lucie, Morschhauser Franck, Tilly Herve, Ribrag Vincent, Lamy Thierry, Thieblemont Catherine, Maisonneuve Herve Gerard, Gressin Remy, Bouabdallah Krimo, Haioun Corinne, Damaj Gandhi, Fornecker Luc-Matthieu, Bouabdallah Reda, Feugier Pierre, Sibon David, Cartron Guillaume, Bonnet Christophe, ANDRÉ Marc, Chartier Loic, Ruminy Philippe, Kraeber-Bodere F, Bodet-Milin C, Berriolo-Riedinger Alina, Briere Josette, Jais Jean-Philippe, Molina Thierry, Itti Emmanuel, Casasnovas Olivier. Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA. Blood, American Society of Hematology, 2020, ⟨10.1182/blood.2020008750⟩
dcterms:title
Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA
dc:date
2020 2021
bibo:doi
10.1182/blood.2020008750